INVO Fertility, Inc (NASDAQ:IVF) Stock Short Interest Declines 71.4%

INVO Fertility, Inc (NASDAQ:IVF) was the target of a significant drop in short interest in the month of October. As of October 30th, there was short interest totaling 7,572 shares, a drop of 71.4% from the October 15th total of 26,478 shares. Approximately 1.2% of the company’s stock are sold short. Based on an average daily trading volume, of 31,162 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on IVF shares. Wall Street Zen upgraded INVO Fertility to a “hold” rating in a report on Saturday, August 29th. Weiss Ratings restated a “sell (e+)” rating on shares of INVO Fertility in a research report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, INVO Fertility currently has an average rating of “Moderate Buy” and an average target price of $320.00.

INVO Fertility Stock Down 3.0%

Shares of NASDAQ:IVF traded down $0.08 during trading on Friday, reaching $2.60. 26,254 shares of the company traded hands, compared to its average volume of 431,634. The firm has a fifty day simple moving average of $10.69 and a 200 day simple moving average of $32.25. The company has a quick ratio of 0.67, a current ratio of 0.71 and a debt-to-equity ratio of 0.03. INVO Fertility has a 1-year low of $1.59 and a 1-year high of $91.60. The firm has a market cap of $1.64 million, a P/E ratio of -0.02 and a beta of 2.42.

INVO Fertility (NASDAQ:IVF) last posted its quarterly earnings results on Friday, August 14th. The company reported $5.60 earnings per share for the quarter. The business had revenue of $2.18 million for the quarter. INVO Fertility had a negative net margin of 116.29% and a negative return on equity of 85.54%.

About INVO Fertility

INVO Fertility, Inc. is a commercial-stage fertility company focused on expanding access to assisted reproductive technology. The company develops and commercializes fertility products and services designed to provide alternatives to conventional in vitro fertilization (IVF) treatment. Its principal product is INVOcell, a medical device used in the INVO Procedure. The system allows early-stage embryo incubation to take place inside the patient’s body rather than in a conventional laboratory incubator, while still involving the retrieval of eggs, fertilization, and subsequent embryo transfer under the supervision of fertility professionals.